- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
AAV Gene Therapy Shows Promise for Congestive Heart Failure
May 18, 2022
A first-in-human dose-escalation trial of a novel gene therapy suggests use was associated with clinically meaningful improvements in NYHA class and LVEF among patients with congestive heart failure.
Study Details Significant Differences in CV Mortality Among Subgroups of Asian Americans
May 10, 2022
An analysis from Northwestern Medicine provides insight into differences in cardiovascular disease mortality among subgroups of Asian Americans.
Uncontrolled Blood Pressure, HbA1c Common Among Hospitalized Heart Failure Patients
May 09, 2022
An analysis of NHANES surveys from 2001-2018 describes the overall prevalence of uncontrolled hypertension and HbA1c in adults with heart failure and provides insight into racial/ethnic disparities in prevalence.
Dapagliflozin Meets Primary Endpoint in Phase 3 DELIVER Trial
May 05, 2022
AstraZeneca announced the phase 3 DELIVER trial has met its primary endpoint, with use of dapagliflozin associated with a statistically significant and clinically meaningful reduction in the primary composite endpoint of CV death or worsening heart failure in patients with HFmrEF and HFpEF.
Don't Miss a Beat: Interpreting New Heart Failure Guidelines
May 04, 2022
In this episode of Don't Miss a Beat, hosts Drs. Greene and Vaduganathan break down the new ACC/AHA/HFSA heart failure guidelines debuted at ACC.22 and compare the recommendations against those made in the European Society of Cardiology's 2021 heart failure guidelines.
Subcutaneous ICDs Could Reduce Risk of Lead-Related Complications
May 03, 2022
Data from the ATLAS trial suggests receiving an S-ICD was associated with a 92% lower risk of major lead-related complications compared to receiving a TV-ICD.
SGLT2 Inhibitor Prescriptions Increasing Among Cardiologists, Still Room for Improvement
April 28, 2022
An analysis of national prescription data suggests the number of prescriptions for SGLT2 inhibitors from cardiologists increased 12-fold from 2015 to 2020 while prescriptions for GLP-1 RAs increased 4-fold during the same period.
Cardiology Month in Review: April 2022
April 23, 2022
Our cardiology month in review spotlights the most popular articles from the past month. This month's top articles include new heart failure guidelines, data from ACC.22, and more!
Initial Dips in eGFR Common with SGLT2 Inhibitors, Not Cause for Long-Term Concern
April 22, 2022
A post hoc analysis of DAPA-HF details the occurrence of eGFR declines within the first 14 days of starting therapy with dapagliflozin and the association of these declines with outcomes in the trial.
History of Infertility Linked to Increased Risk of Heart Failure in Women
April 19, 2022
An analysis of data from more than 35,000 women in the Women's Health Initiative indicates a history of infertility was independently associated with a 16% increase in risk of incident heart failure, with a 27% increase in risk of HFpEF, in postmenopausal women.